An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1
An Exploratory Study of FE999908 in Patients With Hepatorenal Syndrome Type 1
This is an open-label, multi-center study, investigating the efficacy and safety of terlipressin in Japanese patients with hepatorenal syndrome type 1.
Inclusion Criteria:
- Patients who were diagnosed with HRS type 1 according to the diagnostic criteria of HRS and whose serum creatinine value (SCr) doubled at 2.5 mg/dL or greater within 2 weeks or whose 24h creatinine clearance (Ccr) decreased by half at less than 20 mL/min.
Patients should meet all the following 5 criteria:
[Modified International Ascites Club's Diagnostic criteria of HRS]
Chronic or acute liver disease with advanced hepatic failure and portal hypertension.
Low glomerular filtration rate (SCr >1.5 mg/dL or 24h Ccr <40 mL/min)
Absence of shock, ongoing bacterial infection, current or recent (within 2 weeks) treatment with nephrotoxic drug
No sustained improvement in renal function (decrease in SCr to 1.5 mg/dL or less or increase in 24h Ccr to 40 mL/min or more) following diuretic withdrawal and expansion of plasma volume with 1,500 mL/24h of isotonic saline for 24 to 48h.
Protein urea <500 mg/dL, and no ultrasonographic evidence of obstructive uropathy or parenchymal renal disease
Exclusion Criteria:
Kansai, Japan
Kanto, Japan